摘要
背景:HER-2基因为人表皮生长因子受体(EGFR)家族成员之一,在多种肿瘤中过表达。研究发现针对HER-2基因的靶向治疗可显著延长进展期胃癌/食管胃交界部腺癌患者的生存期。目的:研究HER-2蛋白在进展期不同部位胃癌中的表达情况。方法:应用免疫组化SP法对2012年2月-2013年8月安阳市肿瘤医院783例进展期胃癌行HER-2蛋白表达的检测,比较不同部位胃癌中HER-2蛋白阳性表达率。结果:食管胃交界部腺癌中的HER-2蛋白阳性表达率显著高于胃体腺癌和胃窦/幽门部腺癌(12.7%对6.7%和8.3%,P<0.05),而胃体腺癌与胃窦/幽门部腺癌之间HER-2蛋白阳性表达率无明显差异(P>0.05)。结论:HER-2蛋白阳性表达率可能与胃癌发生部位有关。
Background: HER-2 gene is a member of human epidermal growth factor receptor( EGFR) family,and is overexpressed in many tumors. Studies have shown that HER-2-targeted therapy can significantly prolong the survival of patients with advanced gastric /esophagogastric junction adenocarcinoma. Aims: To study the expression of HER-2 protein in advanced gastric cancer of different sites. Methods: HER-2 protein expression in 783 patients with advanced gastric cancer from Feb. 2012 to Aug. 2013 at Anyang Tumor Hospital was detected by immunohistochemical SP staining,and positivity rates of HER-2 protein expression in gastric cancer of different sites were compared. Results: The positivity rate of HER-2 protein expression in esophagogastric junction adenocarcinoma was significantly higher than that in gastric body adenocarcinoma and antrum /pylorus adenocarcinoma( 12. 7% vs. 6. 7%,8. 3%,P < 0. 05). However,no significant difference in positivity rate of HER-2 protein expression was found between gastric body adenocarcinoma and antrum /pylorus adenocarcinoma( P > 0. 05). Conclusions: The positivity rate of HER-2 protein expression may be related with the site of gastric cancer.
出处
《胃肠病学》
2014年第10期618-620,共3页
Chinese Journal of Gastroenterology
